Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA partners with Medicare & Medicaid to promote common evaluation

This article was originally published in SRA

Executive Summary

The US Food and Drug Administration has signed an agreement with the Centers for Medicare and Medicaid Services to enhance information sharing between the agencies. The agreement would satisfy their common needs for evaluating the safety, efficacy, utilisation, coverage, payment and clinical benefit of drugs, biologics and medical devices1.

You may also be interested in...



COVID-19 Vaccines Donated To Philippines Require Emergency Use Authorization

Days after a senior Chinese government official offered free COVID-19 vaccines to the Philippines government, the country’s medicines regulator said the donated jabs would need an emergency approval before they can be used on the public.

EDQM Sets 2023 Target For Modernizing ‘Certificates Of Suitability’

The European Directorate for the Quality of Medicines & HealthCare is proceeding carefully to find the right balance between serving the diverse requirements of various stakeholders that make use of its ‘certificates of suitability.’

Global Regulators Issue Advice On Clinical Comparability Of Biosimilar MAbs

The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.

UsernamePublicRestriction

Register

LL1129552

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel